Prolira Revenue and Competitors

Prolira is all about safe and accurate delirium monitoring in routine hospital care. Delirium (acute brain failure) affects over 3 million hospitalised patients in Europe every year. It is a potentially fatal medical emergency that regularly leads to long-term cognitive impairment (dementia), results in longer hospital admission, and directly contributes to higher healthcare costs. Delirium equals diabetes in societal costs, estimated at €173 billion. The longer a delirium episode lasts, the more damage is done. To date, delirium is detected too little and too late, as detection is based on subjective and ineffective methods. It is our challenge to solve the unmet clinical need for accurate and safe delirium detection, ànd making the solution fit into routine care. Prolira, a spin-off from the University Medical Center Utrecht (NL), responds to this market need through the introduction of an innovative, non-invasive medical device for delirium detection. Prolira's EEG-based device consists of a single use electrode patch (the DeltaScan Patch) and a hardware/software module (the DeltaScan Monitor), that analyses brain activity. DeltaScan is a breakthrough for delirium recognition and treatment. By early detection and more detection, Prolira tackles the problem at the source.